- Home
- VIR vs PVLA Comparison
VIR vs PVLA Comparison
Compare VIR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- PVLA
- Stock Information
- Founded
- VIR 2016
- PVLA 2015
- Country
- VIR United States
- PVLA United States
- Employees
- VIR N/A
- PVLA N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- VIR Health Care
- PVLA Health Care
- Exchange
- VIR Nasdaq
- PVLA Nasdaq
- Market Cap
- VIR 706.4M
- PVLA 604.2M
- IPO Year
- VIR 2019
- PVLA N/A
- Fundamental
- Price
- VIR $5.63
- PVLA $70.46
- Analyst Decision
- VIR Strong Buy
- PVLA Strong Buy
- Analyst Count
- VIR 11
- PVLA 12
- Target Price
- VIR $25.73
- PVLA $66.67
- AVG Volume (30 Days)
- VIR 1.1M
- PVLA 183.1K
- Earning Date
- VIR 10-30-2025
- PVLA 11-15-2025
- Dividend Yield
- VIR N/A
- PVLA N/A
- EPS Growth
- VIR N/A
- PVLA N/A
- EPS
- VIR N/A
- PVLA N/A
- Revenue
- VIR $19,000,000.00
- PVLA N/A
- Revenue This Year
- VIR N/A
- PVLA N/A
- Revenue Next Year
- VIR $15.25
- PVLA N/A
- P/E Ratio
- VIR N/A
- PVLA N/A
- Revenue Growth
- VIR N/A
- PVLA N/A
- 52 Week Low
- VIR $4.16
- PVLA $11.17
- 52 Week High
- VIR $14.45
- PVLA $72.42
- Technical
- Relative Strength Index (RSI)
- VIR 59.22
- PVLA 76.18
- Support Level
- VIR $5.36
- PVLA $60.49
- Resistance Level
- VIR $6.00
- PVLA $65.43
- Average True Range (ATR)
- VIR 0.28
- PVLA 3.88
- MACD
- VIR 0.03
- PVLA 0.59
- Stochastic Oscillator
- VIR 65.62
- PVLA 86.60
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.